{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:02:43Z","timestamp":1790856163433,"version":"4.1.0"},"reference-count":83,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>The growing population of cancer survivors has brought to light the critical challenge of cancer therapy-related cardiac dysfunction, particularly with the use of anthracyclines, HER2-targeted agents and other novel therapeutics. This review aims to support the personalized integration of cardiovascular risk management into oncology care to optimize long-term patient outcomes. We summarize the outline approaches to patient risk assessment and surveillance, and present evidence-based non-pharmacological and pharmacological strategies for cardioprotection during cancer treatment. These strategies highlight recent data supporting the emerging cardioprotective role of exercise training, as well as the use of SGLT2 inhibitors, ACE inhibitors, angiotensin receptor blockers, sacubitril\/valsartan, beta-blockers, mineralocorticoid receptor antagonists, statins and dexrazoxane. We present a comprehensive synthesis emphasizing the critical role of cardio-oncology in identifying patients at high risk, understanding clinical outcomes, and implementing practical, evidence-based strategies. Our findings underscore the need for proactive cardiovascular risk management to enhance long-term care in oncology patients.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-treatment-of-left-ventricular-dysfunction-during-cancer-therapy-a-comprehensive-review<\/jats:p>","DOI":"10.7573\/dic.2025-10-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:36:41Z","timestamp":1775075801000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review"],"prefix":"10.7573","author":[{"given":"Edgardo","family":"Kaplinsky","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0495vrm88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Municipal de Badalona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Barbagelata","sequence":"additional","affiliation":[{"name":"Universidad Cat\u00f3lica Argentina, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Hospital Sirio Libanes, Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline O","family":"Fischer-Bacca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ny5wp25","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade para o Desenvolvimento do Alto Vale do Itaja\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tFlorido R, Daya NR, Ndumele CE, et al. Cardiovascular disease risk among cancer survivors: the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol. 2022;80(1):22\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.042","DOI":"10.1016\/j.jacc.2022.04.042"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tNg HS, Meng R, Marin TS, et al. Cardiovascular mortality in people with cancer compared to the general population: a systematic review and meta-analysis. Cancer Med. 2024;13(15):e70057. https:\/\/doi.org\/10.1002\/ cam4.70057","DOI":"10.1002\/cam4.70057"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tCamilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2024;6(5):655\u2013677. https:\/\/doi.org\/10.1016\/ j.jaccao.2024.07.016","DOI":"10.1016\/j.jaccao.2024.07.016"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tBrauer J, Tumani M, Frey N, Lehmann LH. The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models. Basic Res Cardiol. 2025;120(1):91\u2013112. https:\/\/doi.org\/10.1007\/s00395-024- 01090-w","DOI":"10.1007\/s00395-024-01090-w"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tRaman HS, Mitchell J, Nohria A, Upshaw JN, LaCasce AS. Cardiovascular and oncologic considerations in adult hodgkin lymphoma: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2025;7(7):781\u2013799. https:\/\/doi.org\/10.1016\/j.jaccao.2025.07.011","DOI":"10.1016\/j.jaccao.2025.07.011"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tNielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024;10(10):1390\u20131399. https:\/\/doi.org\/10.1001\/jamaoncol. 2024.3065","DOI":"10.1001\/jamaoncol.2024.3065"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tSayegh N, Yirerong J, Agarwal N, et al. Cardiovascular toxicities associated with tyrosine kinase inhibitors. Curr Cardiol Rep. 2023;25(4):269\u2013280. https:\/\/doi.org\/10.1007\/s11886-023-01845-2","DOI":"10.1007\/s11886-023-01845-2"},{"key":"ref8","unstructured":"9.\tLyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u20134361. https:\/\/doi.org\/ 10.1093\/eurheartj\/ehac244"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tHerrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u2013299. https:\/\/doi.org\/10.1093\/ eurheartj\/ehab674","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tZhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u20131642. https:\/\/doi.org\/10.1038\/nm.2919","DOI":"10.1038\/nm.2919"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tMincu RI, Mahabadi AA, Michel L, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890. https:\/\/doi.org\/10.1001\/ jamanetworkopen.2019.8890","DOI":"10.1001\/jamanetworkopen.2019.8890"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tCronin M, Crowley A, Davey MG, et al. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-positive breast cancer. J Clin Med. 2023;12(4):1278. https:\/\/doi.org\/10.3390\/jcm12041278","DOI":"10.3390\/jcm12041278"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tJohnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","DOI":"10.1056\/NEJMoa1609214"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tMoslehi JJ, Johnson DB, Sosman JA. Myocarditis with immune checkpoint blockade. N Engl J Med. 2017;376(3):292. https:\/\/doi.org\/10.1056\/NEJMc1615251","DOI":"10.1056\/NEJMc1615251"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tRodr\u00edguez-Hern\u00e1ndez MA, de la Cruz-Ojeda P, L\u00f3pez-Grueso MJ, et al. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020;36:101510. https:\/\/doi.org\/10.1016\/j.redox.2020.101510","DOI":"10.1016\/j.redox.2020.101510"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tWang H, Wang Y, Li J, et al. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. https:\/\/doi.org\/10.1186\/s12916-023-02838-2","DOI":"10.1186\/s12916-023-02838-2"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tTotzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928\u20131940. https:\/\/doi.org\/10.1093\/eurheartj\/ehac106","DOI":"10.1093\/eurheartj\/ehac106"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tBelzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc. 2021;10(18):e021686. https:\/\/doi.org\/10.1161\/JAHA.121.021686","DOI":"10.1161\/JAHA.121.021686"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tBergom C, Bradley JA, Ng AK, et al. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncology. 2021;3(3):343\u2013359. https:\/\/doi.org\/10.1016\/ j.jaccao.2021.06.007","DOI":"10.1016\/j.jaccao.2021.06.007"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tLyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u20131960. https:\/\/doi.org\/10.1002\/ejhf.1920","DOI":"10.1002\/ejhf.1920"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tThavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.020","DOI":"10.1016\/j.jacc.2020.11.020"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tHaj-Yehia E, Michel L, Mincu RI, Rassaf T, Totzeck M. Prevention of cancer-therapy related cardiac dysfunction. Curr Heart Fail Rep. 2025;22(1):9. https:\/\/doi.org\/10.1007\/s11897-025-00697-x","DOI":"10.1007\/s11897-025-00697-x"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tS\u0142awi\u0144ski G, Hawryszko M, Li\u017cewska-Springer A, Nabia\u0142ek-Trojanowska I, Lewicka E. Global longitudinal strain in cardio-oncology: a review. Cancers. 2023;15(3):986. https:\/\/doi.org\/10.3390\/cancers15030986","DOI":"10.3390\/cancers15030986"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tBertolini D, Pizzi C, Donal E, Galli E. Cancer and heart failure: dangerous liaisons. J Cardiovasc Dev Dis. 2024;11(9):263. https:\/\/doi.org\/10.3390\/jcdd11090263","DOI":"10.3390\/jcdd11090263"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tAddison D, Neilan TG, Barac A, et al. American Heart Association Council on Cardiovascular Radiology and Intervention; Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and Council on Cardiovascular and Stroke Nursing. Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2023;148(16):1271\u20131286. https:\/\/doi.org\/10.1161\/CIR.0000000000001174","DOI":"10.1161\/CIR.0000000000001174"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tL\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720\u20131729. https:\/\/doi.org\/10.1093\/ eurheartj\/ehaa006","DOI":"10.1093\/eurheartj\/ehaa006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tRivero-Santana B, Salda\u00f1a-Garc\u00eda J, Caro-Cod\u00f3n J, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025;46(3):273\u2013284. https:\/\/doi.org\/10.1093\/eurheartj\/ehae496","DOI":"10.1093\/eurheartj\/ehae818"},{"key":"ref28","unstructured":"29.\tDenegri A, Moccetti T, Moccetti M, Spallarossa P, Brunelli C, Ameri P. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016;13(4):355\u2013363. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.04.010"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tTorrente M, Blanco M, Franco F, et al. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Front Cardiovasc Med. 2022;9:1062858. https:\/\/doi.org\/10.3389\/fcvm.2022.1062858","DOI":"10.3389\/fcvm.2022.1062858"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tCarlson LE, Watt GP, Tonorezos ES, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncology. 2021;3(3):381\u2013392. https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.008","DOI":"10.1016\/j.jaccao.2021.07.008"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tBattisti NML, Welch CA, Sweeting M, et al. Prevalence of cardiovascular disease in patients with potentially curable malignancies: a National Registry Dataset Analysis. JACC CardioOncology. 2022;4(2):238\u2013253. https:\/\/doi.org\/10.1016\/j.jaccao.2022.03.004","DOI":"10.1016\/j.jaccao.2022.03.004"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tKim Y, Seidman JG, Seidman CE. Genetics of cancer therapy-associated cardiotoxicity. J Mol Cell Cardiol. 2022;167:85\u201391. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.03.010","DOI":"10.1016\/j.yjmcc.2022.03.010"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tYamada T, Nomura S. Recent findings related to cardiomyopathy and genetics. Int J Mol Sci. 2021;22(22):12522. https:\/\/doi.org\/10.3390\/ijms222212522","DOI":"10.3390\/ijms222212522"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tBoen HM, Alaerts M, Goovaerts I, et al. Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study. Cardio-Oncology. 2024;10(1):26. https:\/\/doi.org\/10.1186\/s40959-024-00231-3","DOI":"10.1186\/s40959-024-00231-3"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tScalia IG, Gheyath B, Tamarappoo BK, et al. Chemotherapy related cardiotoxicity evaluation - a contemporary review with a focus on cardiac imaging. J Clin Med. 2024;13(13):3714. https:\/\/doi.org\/10.3390\/jcm13133714","DOI":"10.3390\/jcm13133714"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tHaykowsky MJ, Kirkham AA, Li T, et al. Determinants of oxygen utilization in breast cancer: similarities between heart failure with preserved ejection fraction. Prog Cardiovasc Dis. 2022;74:45\u201352. https:\/\/doi.org\/10.1016\/j.pcad.2022.10.005","DOI":"10.1016\/j.pcad.2022.10.005"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tHowden EJ, Foulkes S, Dillon HT, et al. Traditional markers of cardiac toxicity fail to detect marked reductions in cardiorespiratory fitness among cancer patients undergoing anti-cancer treatment. Eur Heart J Cardiovasc Imaging. 2021;22(4):451\u2013458. https:\/\/doi.org\/10.1093\/ehjci\/jeaa421","DOI":"10.1093\/ehjci\/jeaa421"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tHowden EJ, Bigaran A, Beaudry R, et al. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol. 2019;26(3):305\u2013315. https:\/\/doi.org\/ 10.1177\/2047487318811181","DOI":"10.1177\/2047487318811181"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tNaaktgeboren WR, Groen WG, Jacobse JN, et al. Physical activity and cardiac function in long-term breast cancer survivors: a cross-sectional study. JACC CardioOncology. 2022;4(2):183\u2013191. https:\/\/doi.org\/10.1016\/j.jaccao.2022.02.007","DOI":"10.1016\/j.jaccao.2022.02.007"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tFoulkes SJ, Howden EJ, Haykowsky MJ, et al. Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation. 2023;147(7):532\u2013545. https:\/\/doi.org\/10.1161\/ CIRCULATIONAHA.122.062814","DOI":"10.1161\/CIRCULATIONAHA.122.062814"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tGilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997\u2013e1012. https:\/\/doi.org\/10.1161\/CIR.0000000000000711","DOI":"10.1161\/CIR.0000000000000679"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tScott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36(22):2297\u20132305. https:\/\/doi.org\/10.1200\/ JCO.2017.77.5809","DOI":"10.1200\/JCO.2017.77.5809"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tChiang CH, Chang YC, Haw Y, Tan JY, Chiang CH, Hsia YP, Chiang CH. The effect of exercise on cardiotoxicity in women with breast cancer receiving anthracycline-based chemotherapy: a systematic review and meta-analysis. Oncology. 2024;102(6):510\u2013514. https:\/\/doi.org\/10.1159\/000535737","DOI":"10.1159\/000535737"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tMcMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tDabour MS, Blaes AH, Ramu B, Zordoky BN. SGLT2 inhibitors in mitigating cancer therapy-related cardiac dysfunction: expanding the evidence. JACC CardioOncology. 2024;6(6):876\u2013878. https:\/\/doi.org\/10.1016\/j. jaccao.2024.10.005","DOI":"10.1016\/j.jaccao.2024.10.005"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tOh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J. 2019;49(12):1183\u20131195. https:\/\/doi.org\/10.4070\/kcj.2019.0180","DOI":"10.4070\/kcj.2019.0180"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tGongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559\u2013567. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006","DOI":"10.1016\/j.jchf.2022.03.006"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tDaniele AJ, Gregorietti V, Costa D, L\u00f3pez-Fern\u00e1ndez T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial. Cardio-Oncology. 2024;10(1):58. https:\/\/doi.org\/10.1186\/s40959-024-00260-y","DOI":"10.1186\/s40959-024-00260-y"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tGreco A, Quagliariello V, Rizzo G, et al. SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +\/-trastuzumab: rationale and design of the multicenter PROTECT trial. Cardio-Oncology. 2025;11(1):79. https:\/\/doi. org\/10.1186\/s40959-025-00368-9","DOI":"10.1186\/s40959-025-00368-9"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tPerelman MG, Brzezinski RY, Waissengrin B, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardio-Oncology. 2024;10(1):2. https:\/\/doi.org\/10.1186\/ s40959-023-00199-6","DOI":"10.1186\/s40959-023-00199-6"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tWannaphut C, Wattanachayakul P, Saowapa S, et al. Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis. Ecancermedicalscience. 2025;19:1844. https:\/\/doi.org\/10.3332\/ecancer.2025.1844","DOI":"10.3332\/ecancer.2025.1844"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tLiu HY, Lv YD, Chen YQ, et al. Empagliflozin protects against doxorubicin-induced arrhythmia by AMPK\/ mTOR-mediated autophagy in cardiomyocyte. Eur J Pharmacol. 2026;1014:178520. https:\/\/doi.org\/10.1016\/ j.ejphar.2026.178520","DOI":"10.1016\/j.ejphar.2026.178520"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tHsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL, Chan SH. Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation. Int J Mol Sci. 2022;23(17):10146. https:\/\/doi.org\/10.3390\/ijms231710146","DOI":"10.3390\/ijms231710146"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tSOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","DOI":"10.1056\/NEJM199108013250501"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tPitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582\u20131587. https:\/\/doi.org\/10.1016\/S0140-6736(00)02213-3","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tGao Y, Wang R, Jiang J, Hu Y, Li H, Wang Y. ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. Heart Fail Rev. 2023;28(6): 1405\u20131415. https:\/\/doi.org\/10.1007\/s10741-023-10328-z","DOI":"10.1007\/s10741-023-10328-z"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tFerrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017;125(Pt A):57\u201371. https:\/\/doi.org\/10.1016\/j.phrs.2017.05.020","DOI":"10.1016\/j.phrs.2017.05.020"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tFang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2021;26(1):101\u2013109. https:\/\/doi.org\/10.1007\/s10741-019-09906-x","DOI":"10.1007\/s10741-019-09906-x"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tLin H, Liang G, Wu Y, Chen L. Protective effects of ACEI\/ARB on left ventricular function in anthracycline-induced chronic cardiotoxicity: a meta-analysis of randomized controlled trials. Cardiology. 2021;146(4):469\u2013480. https:\/\/doi.org\/10.1159\/000512848","DOI":"10.1159\/000512848"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tMcMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tDocherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril\/Valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020;8(10):800\u2013810. https:\/\/doi.org\/10.1016\/j.jchf.2020.06.020","DOI":"10.1016\/j.jchf.2020.06.020"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tOmland T, Heck SL, Holte E, et al. Sacubitril-valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial. Circulation. 2025;152:1136\u20131145. https:\/\/doi.org\/10.1161\/ CIRCULATIONAHA.125.076616","DOI":"10.1161\/CIRCULATIONAHA.125.076616"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tH\u00fcntermann R, Fischer-Bacca CO, Alves MF, et al. Sacubitril-valsartan in cancer therapy-induced heart failure: a systematic review and meta-analysis of functional and hemodynamic parameters. Curr Probl Cardiol. 2025;50(5):102987. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.102987","DOI":"10.1016\/j.cpcardiol.2025.102987"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313. https:\/\/doi. org\/10.1016\/S0140-6736(98)11181-9","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tMERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20132007. https:\/\/doi.org\/10.1016\/ S0140-6736(99)04440-2","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tMa Y, Bai F, Qin F, et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):18. https:\/\/doi.org\/10.1186\/ s40360-019-0298-6","DOI":"10.1186\/s40360-019-0298-6"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tHuang S, Zhao Q, Yang ZG, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev. 2019;24(3):325\u2013333. https:\/\/doi.org\/10.1007\/ s10741-018-9755-3","DOI":"10.1007\/s10741-018-9755-3"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tSolomon SD, Pfeffer MA. Aldosterone antagonism and myocardial infarction: from animals to man and back. J Am Coll Cardiol. 2003;42(9):1674\u20131676. https:\/\/doi.org\/10.1016\/j.jacc.2003.08.008","DOI":"10.1016\/j.jacc.2003.08.008"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tPitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tAkpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81\u201389. https:\/\/doi.org\/10.1002\/ejhf.196","DOI":"10.1002\/ejhf.196"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tLiu X, Ding R, Zhang A. Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis. Front Cardiovasc Med. 2025;12:1612060. https:\/\/doi.org\/10.3389\/fcvm.2025.1612060","DOI":"10.3389\/fcvm.2025.1612060"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tHenninger C, Fritz G. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis. 2017;8(1):e2564. https:\/\/doi.org\/10.1038\/cddis.2016.418","DOI":"10.1038\/cddis.2016.418"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tSchupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis. 2008;199(2):278\u2013287. https:\/\/doi.org\/10.1016\/ j.atherosclerosis.2007.11.016","DOI":"10.1016\/j.atherosclerosis.2007.11.016"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tTitus A, Cheema HA, Shafiee A, et al. Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(10):101885. https:\/\/doi.org\/10.1016\/ j.cpcardiol.2023.101885","DOI":"10.1016\/j.cpcardiol.2023.101885"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tFelix N, Nogueira PC, Silva IM, et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2024;126:43\u201348. https:\/\/doi.org\/10.1016\/j.ejim.2024.04.007","DOI":"10.1016\/j.ejim.2024.04.007"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tBhasin V, Vakilpour A, Scherrer-Crosbie M. Statins for the primary prevention of anthracycline cardiotoxicity: a comprehensive review. Curr Oncol Rep. 2024;26(10):1197\u20131204. https:\/\/doi.org\/10.1007\/s11912-024-01579-6","DOI":"10.1007\/s11912-024-01579-6"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tDeng S, Yan T, Jendrny C, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:842. https:\/\/doi.org\/10.1186\/1471-2407-14-842","DOI":"10.1186\/1471-2407-14-842"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tMacedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncology. 2019;1(1):68\u201379. https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.003","DOI":"10.1016\/j.jaccao.2019.08.003"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tde Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. https:\/\/doi.org\/10.1002\/14651858.CD014638.pub2","DOI":"10.1002\/14651858.CD014638.pub2"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tLiu G, Liu Y, Wang R, et al. Spironolactone attenuates doxorubicin-induced cardiotoxicity in rats. Cardiovasc Ther. 2016;34(4):216\u2013224. https:\/\/doi.org\/10.1111\/1755-5922.12189","DOI":"10.1111\/1755-5922.12189"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tBiondi F, Madonna R. The potential role of GLP1-RAs against anticancer-drug cardiotoxicity: a scoping review. J Clin Med. 2025;14(8):2705. https:\/\/doi.org\/10.3390\/jcm14082705","DOI":"10.3390\/jcm14082705"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tGao G, Shen C, Wang M, et al. Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7- mediated STAT3 palmitoylation. Life Sci. 2025;379:123912. https:\/\/doi.org\/10.1016\/j.lfs.2025.123912","DOI":"10.1016\/j.lfs.2025.123912"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/04\/dic.2025-10-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:13:28Z","timestamp":1790853208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/treatment-of-left-ventricular-dysfunction-during-cancer-therapy-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":83,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-10-3","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"article-number":"dic.2025-10-3"}}